Basophil activation tests with cryopreserved mRNA-based COVID-19 vaccines

Alcaraz‐Serna, Ana; Noto, Alessandra; Ermellino, Laura; Monzambani-Banderet, Véronique; Tommasini, Francesco; Stehlin, Florian; Girard, Cedric; Perreau, Matthieu; Müller, Yannick D.

doi:10.1016/j.alit.2023.03.005

Cited by 2 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Firstly, the mRNA content in the Spikevax vaccine is higher (100 μg) compared to Comirnaty (30 μg). Secondly, the Spikevax vaccine seems more stable in solution than Comirnaty after reconstitution (14). Thus, we recently demonstrated that cell lines become spike protein positive in culture when exposed to Spikevax but not to Comirnaty (14).…”

Section: Discussionmentioning

confidence: 95%

“…We then explored the potential link between vaccine sensitization and CU. To do this, we conducted basophil activation tests (BAT) using a cryopreserved batch of the Spikevax vaccine, which we previously validated (14). Out of 50 blood samples tested, two patients had no basophils, and four were excluded due to basophil areactivity.…”

Section: Resultsmentioning

confidence: 99%

“…Secondly, the Spikevax vaccine seems more stable in solution than Comirnaty after reconstitution (14). Thus, we recently demonstrated that cell lines become spike protein positive in culture when exposed to Spikevax but not to Comirnaty (14). Apart from the dosage differences, the Pfizer and Moderna platforms have few distinctions, with some variations in the structures of LNP carriers.…”

Section: Discussionmentioning

confidence: 99%

“…As previously reported vaccine-sensitization could be assessed by means of CD63 upregulation with Spikevax or Comirnaty in an interchangeable way, as a surrogate of intra-dermal skin test (14). Briefly, blood samples were collected in 3ml EDTA tubes and were used up to 24h of blood collection using the Flow CAST® from Bühlmann Labs according to manufacturer's instructions (FK-CCR).…”

Section: Basophil Activation Testmentioning

confidence: 99%

See 3 more Smart Citations

Features of chronic urticaria after COVID-19 mRNA vaccine, a real-life cohort study

Muller,

Foglierini,

Pescosolido

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

Background New onsets of chronic urticaria (CU) have been reported after repeated immunizations, mainly with the Moderna mRNA-1273 vaccine (Spikevax) Objective This study aims to evaluate patients with CU after COVID-19 mRNA vaccination. The contribution of SARS-Cov2 infection, atopy and IgE against the vaccine was analyzed. Methods We monitored the features of patients who developed CU after vaccination in the Canton of Vaud through two surveys conducted in 2022 and 2023. Fifty individuals with CU underwent blood tests, and their results were compared with individuals without a history of urticaria (N=135). The presence of anti-vaccine IgE was detected with basophil activation tests (BAT). We assessed anti-SARS-Cov2 humoral response, and the presence of IgEs against common respiratory allergens (Phadiatop) as a surrogate for atopy. Results Post-vaccination CU occurred after a median interval of 10 days and significantly more after the Spikevax booster, affecting middle-aged individuals (median 41, 66% females). In 2023, CU was still active in 53% of the cases. Inducible forms of CU, primarily dermographism, were reported in 54% (2022) and 61% (2023) of the cases. BAT positivity was not specific to CU, anti-nucleocapsid positivity, or atopy but was significantly associated with higher anti-spike neutralizing activities and younger age. Four CU patients tolerated an additional dose of mRNA vaccine with no disease exacerbation/recurrence. Conclusion The Spikevax booster induced anti-vaccine IgE independently of CU, the latter being not directly associated with COVID-19 infection nor atopy. The tolerance to a new booster in 4/4 patients suggests that the Spikevax vaccine indirectly triggered CU in predisposed individuals.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Basophil Activation Testmentioning

confidence: 99%

See 2 more Smart Citations

Features of chronic urticaria after COVID-19 mRNA vaccine, a real-life cohort study

Muller,

Foglierini,

Pescosolido

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

Features of chronic urticaria after COVID-19 mRNA vaccine over time

Schwab,

Foglierini,

Pescosolido

et al. 2024

Commun Med

View full text Add to dashboard Cite

Background New onsets of chronic urticaria (CU) have been reported after repeated immunizations, mainly with the Moderna mRNA-1273 vaccine (Spikevax). This study aims to evaluate patients with CU after COVID-19 mRNA vaccination. The contribution of SARS-Cov2 infection, atopy and IgE against the vaccine was analyzed. Methods We monitored the features of patients who developed CU after vaccination through two surveys conducted in 2022 and 2023. Fifty individuals with CU underwent blood tests, and their results were compared with individuals without a history of urticaria ( N = 135). The presence of anti-vaccine IgE was tested in 185 individuals with basophil activation tests (BAT). We assessed anti-SARS-Cov2 humoral response, and the presence of IgEs against common respiratory allergens (Phadiatop) as a surrogate for atopy. Results Post-vaccination CU occurs after a median interval of 10 days and significantly more after the Spikevax booster, affecting middle-aged individuals (median 41, 66% females). In 2023, CU was still active in 53% of the cases. Inducible forms of CU, primarily dermographism, are reported in 54% (2022) and 61% (2023) of the cases. BAT positivity is not specific to CU, anti-nucleocapsid positivity, or atopy but is significantly associated with higher anti-spike neutralizing activities and younger age. Four CU patients tolerate an additional dose of mRNA vaccine with no disease exacerbation/recurrence. Conclusions The spikevax booster induces anti-vaccine IgE independently of CU, the latter being not directly associated with COVID-19 infection nor atopy. The tolerance to a new booster in 4/4 patients suggests that the Spikevax vaccine indirectly triggers CU in predisposed individuals.

show abstract

Basophil activation tests with cryopreserved mRNA-based COVID-19 vaccines

Cited by 2 publications

References 9 publications

Features of chronic urticaria after COVID-19 mRNA vaccine, a real-life cohort study

Features of chronic urticaria after COVID-19 mRNA vaccine, a real-life cohort study

Features of chronic urticaria after COVID-19 mRNA vaccine over time

Contact Info

Product

Resources

About